Pathological thickening of the cardiac wall halted

The heart responds to the increased stress caused by chronically raised blood pressure, for example, by thickening its wall muscle. In the late stage of this condition, a risk of heart failure arises.

Scientists from the Max Planck Institute for Heart and Lung Research have now succeeded in identifying a key molecule in the molecular signalling cascade responsible for this growth. Based on this discovery, they managed to achieve a significant reduction in cardiac wall thickening in animal experiments. In addition, they managed to partly reduce existing thickening of the cardiac wall.

The heart reacts to intensive, long-term stress by increasing its muscle mass. In competitive athletes, this thickening of the cardiac wall is known as athletic heart syndrome or “athlete’s heart”. Whereas in this case, the process is a reversible physiological reaction to physical activity, in other cases, cardiac wall thickening, known medically as cardiac hypertrophy, is a serious condition; its progression frequently leads to death through heart failure. The triggers for this pathological change can include, for example, high blood pressure, arteriosclerosis and cardiac valve defects.

Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now identified a crucial interface in the signalling cascade that controls the emergence of cardiac hypertrophy at molecular level. The interface in question is a molecule called RhoGEF12. The crucial indicator was revealed to the researchers in studies on mice, in which the aorta had been artificially narrowed, thereby triggering the development of hypertrophy. “We observed a clear increase in RhoGEF12 activation in the cardiac muscle cells of these mice, “ said Nina Wettschureck, who carried out the study in collaboration with Mikito Takefuji. The Max Planck researchers then used genetically modified mice in which RhoGEF12 could be switched off in cardiac muscle cells in their hypertrophy model. “Four weeks after the beginning of the treatment, the cardiac wall thickening in these mice was clearly less advanced than in animals with RhoGEF12,” explains Wettschureck. In addition, the heart pump output of the mice without RhoGEF12 was considerably better than that in the control group. This led to a higher survival rate in the long term.
An answer to the question as to whether existing hypertrophy can be reversed by switching off RhoGEF12 was important from a clinical perspective. The Bad Nauheim researchers therefore also investigated this possibility. And in fact, a partial reduction of the thickening was observed in mice with existing cardiac hypertrophy in which RhoGEF12 was switched off. “We believe that RhoGEF12 is so important for the hypertrophy reaction because it combines signals from stretch and hormone receptors,” said Wettschureck.

The aim now is to develop a specific therapeutic process based on the insights gained from the study. Wettschureck’s group is thus currently investigating the question as to whether the molecular correlations discovered in the study are completely transferable to humans. Should this be confirmed, the next step should lead to the clinical application of the findings. Wettschureck is optimistic: “Two inhibitors have recently become known, which present possible candidates for a therapy. They could provide a basis for a pharmacological approach.” Another observation made by the study should also prove helpful in terms of developing a new therapeutic approach: the switching off of RhoGEF12 had no side effects in healthy mice.

Contact

Dr. Nina Wettschureck,
Abt. Pharmakologie
Max Planck Institute for Heart and Lung Research, Bad Nauheim
Phone: +49 6032 705-1214
Email: nina.wettschureck@­mpi-bn.mpg.de
Dr. Matthias Heil,
Max Planck Institute for Heart and Lung Research, Bad Nauheim
Phone: +49 6032 705-1705
Fax: +49 6032 705-1704
Email: matthias.heil@­mpi-bn.mpg.de
Original publication
Mikito Takefuji , Marcus Krüger, Kishor K. Sivaraj, Kozo Kaibuchi, Stefan Offermanns, Nina Wettschureck: RhoGEF12 controls cardiac remodelling by integrating G-protein- and integrin-dependent signaling cascades
RhoGEF12 controls cardiac remodeling by integrating G-protein- and integrin-dependent signaling cascades.

Journal of Experimental Medicine 2013. DOI: 10.1084/jem.20122126

Media Contact

Dr. Nina Wettschureck Max-Planck-Institute

All latest news from the category: Life Sciences and Chemistry

Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.

Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors